師資
個人簡介：
王藝瑾，南方科技大學(xué)醫(yī)學(xué)院副教授，博士生導(dǎo)師。2012 年和 2016 年分別于荷蘭瓦赫寧根大學(xué)與研究中心、荷蘭伊拉斯姆斯大學(xué)醫(yī)學(xué)中心獲得碩士和博士學(xué)位。美國伊利諾伊大學(xué)訪問學(xué)者。王藝瑾在國際上較早開展戊型肝炎研究。其課題組以病毒性肝炎的轉(zhuǎn)化研究為核心，通過多組學(xué)分析及篩選技術(shù)，揭示病毒-宿主相互作用、病毒激活及逃逸天然免疫機(jī)制、病毒特異性抵抗干擾素應(yīng)答新機(jī)制，并基于此開發(fā)新型高效抗病毒藥物。同時通過臨床大隊列研究，明確戊型肝炎慢性化、重癥化、肝外感染的危險因素，以及在特殊人群中的預(yù)后判斷。其研究方向還擴(kuò)展到丙型肝炎病毒（HCV）、乙型肝炎病毒（HBV）以及非感染性肝病的發(fā)病機(jī)制研究。依托感染性疾病的研究，課題組同時開展以線粒體動態(tài)調(diào)控為主要研究對象的膿毒癥多器官損傷研究。在非感染性肝病方面，課題組通過單細(xì)胞及空間轉(zhuǎn)錄組測序技術(shù)，揭示非酒精性脂肪肝空間免疫細(xì)胞特征，解釋各種治療手段中，患者不同預(yù)后的免疫學(xué)機(jī)制。
王藝瑾獲得多個人才項目及國家級課題基金資助：入選廣東省珠江人才計劃，入選北京市科技新星計劃，深圳市海外高層次人才B類。入選解放軍總醫(yī)院“3+1”創(chuàng)新人才建設(shè)工程新秀人才，入選解放軍總醫(yī)院優(yōu)青培育計劃；曾承擔(dān)多項荷蘭科技部項目及荷蘭肝腸病協(xié)會課題基金，現(xiàn)主持國家自然科學(xué)基金 3 項， 參與國家科技重大專項等項目； 近年發(fā)表 SCI 論文 48 篇，其中以第一/通訊作者在Lancet Respiratory Medicine，Gastroenterology，Journal of Hepatology， Hepatology，EbioMedicine等知名權(quán)威期刊發(fā)表論文22篇，總影響因子450余分，他引9000余次，主編英文論著 1 本；相關(guān)成果多次被三大國際肝病年會選為口頭報告并獲青年學(xué)者獎。
教育背景：
2012/11–2016/09，荷蘭伊拉斯姆斯大學(xué)醫(yī)學(xué)中心，肝腸病學(xué)，博士
2010/09–2012/08，荷蘭瓦赫寧根大學(xué)與研究中心，生物技術(shù)醫(yī)學(xué)方向，碩士
2006/09–2010/07，南京醫(yī)科大學(xué)，生物技術(shù)，學(xué)士
工作經(jīng)歷：
2020/11-至今， 南方科技大學(xué)醫(yī)學(xué)院，副教授
2016/09-2020/10， 解放軍總醫(yī)院第五醫(yī)學(xué)中心，病理診斷與研究中心，副研究員
獲獎情況及榮譽(yù)：
2021，中華醫(yī)學(xué)科技獎，醫(yī)學(xué)科學(xué)技術(shù)三等獎
2020, 亞太肝病學(xué)會 （APASL）授予的旅行獎
2019， 北京市科委授予的北京市科技新星
2019， 解放軍總醫(yī)院授予的創(chuàng)新人才建設(shè)工程新秀人才
2019， 歐洲肝病學(xué)會（EASL）授予的青年學(xué)者獎
2019， 中美肝病學(xué)院 優(yōu)秀論文報告獎
2019， 北京醫(yī)學(xué)會 北京肝病年會，優(yōu)秀論文
2018, 歐洲肝病年會（EASL）授予的青年學(xué)者獎
2018， 亞太肝病年會（APASL）授予的青年學(xué)者獎
2018， 北京醫(yī)學(xué)會 北京肝病年會，優(yōu)秀論文
2017， 荷蘭肝病學(xué)會（NVGE）授予的 Veldhovenbeurs 獎
2017， 中華醫(yī)學(xué)會 脂肪性肝病聯(lián)合學(xué)術(shù)會議,優(yōu)秀論文
2017， 北京醫(yī)學(xué)會 北京肝病學(xué)術(shù)年會，優(yōu)秀論文
2014， 歐洲肝病年會（EASL）授予的青年學(xué)者獎
研究領(lǐng)域：
其課題組以病毒感染的轉(zhuǎn)化研究為核心，重點研究戊型肝炎病毒（HEV）的感染機(jī)制及開展抗病毒藥物研究。通過結(jié)合最先進(jìn)的分子、細(xì)胞生物學(xué)技術(shù)及多組學(xué)分析，揭示病毒-宿主的相互作用，病毒激活及逃逸天然免疫機(jī)制，并基于此開發(fā)新型高效抗病毒藥物。同時通過臨床大隊列研究，明確HEV感染慢性化、重癥化、肝外感染的危險因素，以及在特殊人群中的預(yù)后判斷。同時，依托感染性疾病的研究，發(fā)現(xiàn)和揭示天然免疫應(yīng)答新機(jī)制，重點關(guān)注于核苷酸合成抑制及線粒體功能調(diào)控。此外，其研究領(lǐng)域還擴(kuò)展到非感染性肝?。ǚ蔷凭灾拘愿尾?、肝細(xì)胞癌、膽管細(xì)胞癌）的無創(chuàng)診斷標(biāo)志物研究。
學(xué)術(shù)任職：
2018 年 7 月 - 至今，中國研究型醫(yī)院學(xué)會分子診斷醫(yī)學(xué)專業(yè)委員會臨床分子檢驗學(xué)組副組長
2018 年 7 月 - 至今，北京醫(yī)學(xué)會肝病學(xué)分會肝病學(xué)分會青年委員
發(fā)表論文：
1. Zhou H#, Dai Z#, Li J, Wang J, Zhu H, Chang X, Wang Y*. TMBIM6 prevents VDAC1 multimerization and improves mitochondrial quality control to reduce sepsis-related myocardial injury. Metabolism. 2023; 140:155383. (Corresponding Author)
2. Zhu H#, Dai Z#, Liu X#, Zhou H, Wang Y*. Serine/threonine kinase 3 promotes oxidative stress and mitochondrial damage in septic cardiomyopathy through inducing Kelch-like ECH-associated protein 1 phosphorylation and nuclear factor erythroid 2-related factor 2 degradation. Int J Biol Sci. 2023 (Corresponding Author)
3. Li R#, Dai Z#, Liu X#, Wang C, Huang J, Xin T, Tong Y, Wang Y*. Interaction between dual specificity phosphatase-1 and cullin-1 attenuates alcohol-related liver disease by restoring p62-mediated mitophagy. Int J Biol Sci. 2023 (Corresponding Author)
4. Wang C, Wang Y*. The role and mechanism of action of mitophagy in various liver diseases. Antioxid Redox Signal. 2022. (Corresponding Author)
5. Li Y, Yu P, Kessler AL, Shu J, Liu X, Liang Z, et al. Wang Y*, Pan Q*. Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology. 2022; 75:196-212. (Co-Corresponding Author)
6. Xu Z#, Shi L#, Wang Y#, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8:420-2. (Co-First Author)
7. Wang Y#, Liu S#, Liu H#, Li W#, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of hepatology. 2020; 73:807-16.
8. Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.Gastroenterology. 2014; 146:1775-83.
9. Wang Y, Chen G, Pan Q, Zhao J. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient. Gastroenterology. 2018; 154:1199-201.
10. Li P, Li Y, Wang Y*, Liu J, Lavrijsen M, Li Y, et al. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. Sci Adv. 2022; 8:eabj5908. (Co-corresponding Author)
11. Wang Y#, Rao H#, Chi X#, Li B#, Liu H, Wu L, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. EBioMedicine. 2019; 46:227-35.
12. Wang Y#*, Wang S#, Wu J#, Jiang Y#, Zhang H, Li S, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. EBioMedicine. 2018; 36:122-30.
13. Wang Y#*, Liu H#, Liu S#, Yang C, Jiang Y, Wang S, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. Liver Int. 2019; 39:2291-300.
14. Wang L, Wang Y*, Liu S, Zhai X, Zhou G, Lu F, et al. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol. 2019. (Co-Corresponding Author)
15. Wang Y, Wang W, Xu L, Zhou X, Shokrollahi E, Felczak K, et al. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy. 2016; 60:2834-48.
16. Wang Y, Liu H, Jiang Y, Pan Q, Zhao J. Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology. Open Forum Infect Dis. 2020; 7:ofaa107.
17. Wang Y, Metselaar HJ, Peppelenbosch MP, Pan Q. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. Current Opinion in Infectious Diseases. 2014; 27:303-8.
18. Wu J, Zhang X, Liu H, Guo N, Pan Q, Wang Y*. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. Clinical Biochemistry. 2019; 63:24-31. (Corresponding Author)
19. Wang Y, Liu S, Pan Q, Zhao J. Chronic hepatitis E in an immunocompetent patient. Clin Res Hepatol Gastroenterol. 2019.
20. Gao Y#, Wang Y#, Liu H#, Liu Z, Zhao J. Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholic steatohepatitis. Dig Liver Dis. 2020; 52:637-43. (Co-First Author)
21. Wang J#, Huang A#, Wang Y#, Ji D, Liang Q, Zhao J, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: A randomised open-label trial. Alimentary Pharmacology & Therapeutics. 2022; Accepted. (Co-First Author)
22. Li S#, Jiang L#, Li X#, Lin F#, Wang Y#, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020; 5. (Co-First Author)
23. Wang W, Wang Y, Qu C, Wang S, Zhou J, Cao W, et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology. 2018; 67:2096-112.
24. Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology. 2014; 61:746-54.
25. Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, et al. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. Antiviral Research. 2017; 140:1-12.
26. Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, et al. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antiviral Research. 2016; 133:41-9.
27. Zhou X, Xu L, Wang Y, Wang W, Sprengers D, Metselaar HJ, et al. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. Antiviral research. 2015; 124:11-9.
28. Dang W, Yin Y, Wang Y, Wang W, Su J, Sprengers D, et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. Antimicrobial agents and chemotherapy. 2017; 61.
29. Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrobial agents and chemotherapy. 2014; 58:267-73.
30. Li M, Wang L, Wang Y, Zhang S, Zhou G, Lieshout R, et al. Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells. 2020; 9.
31. Zhang H, Rao H, Wang Y, Wang J, Kong X, Ji Y, et al. Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection. Journal of gastroenterology and hepatology. 2019; 34:458-65.
32. Zhang S, Qu C, Wang Y, Wang W, Ma Z, Peppelenbosch MP, et al. Conservation and variation of the hepatitis E virus ORF2 capsid protein. Gene. 2018; 675:157-64.
33. Jiang L, Yang M, Li X, Wang Y, Zhou G, Zhao J. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk. The Journal of clinical endocrinology and metabolism. 2018; 103:3974-85.
34. Yang M, Jiang L, Wang Y, Li X, Zou Z, Han T, et al. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease. J Gastrointestin Liver Dis. 2019; 28:289-96.
35. Qu C, Zhang S, Li Y, Wang Y, Peppelenbosch MP, Pan Q. Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Reviews in medical virology. 2019:e2075.
36. Wang W, Yin Y, Xu L, Su J, Huang F, Wang Y, et al. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Science signaling. 2017; 10.
37. Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, et al. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology. 2017; 65:1823-39.
38. Xu L, Zhou X, Wang W, Wang Y, Yin Y, Laan LJ, et al. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-stimulated genes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2016; 30:3352-67.
39. Wang W, Xu L, Brandsma JH, Wang Y, Hakim MS, Zhou X, et al. Convergent Transcription of Interferon-stimulated Genes by TNF-alpha and IFN-alpha Augments Antiviral Activity against HCV and HEV. Scientific reports. 2016; 6:25482.
40. Qu C, Zhang S, Wang W, Li M, Wang Y, van der Heijde-Mulder M, et al. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2019; 33:1008-19.
41. Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. Journal of viral hepatitis. 2016; 23:294-304.
42. Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, et al. Hepatitis E Virus Infects Neurons and Brains. The Journal of infectious diseases. 2017; 215:1197-206.
43. Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, et al. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. Antiviral research. 2015; 123:120-31.
44. Hemachandra LP, Patel H, Chandrasena RE, Choi J, Piyankarage SC, Wang S, et al. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites. Cancer prevention research. 2014; 7:505-15.